Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
03:26pm, Sunday, 07'th Jan 2024
Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.
Isomorphic inks deals with Eli Lilly and Novartis for drug discovery
12:51pm, Sunday, 07'th Jan 2024
Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it's entered into strategic partnerships with two pharmaceutical giants, Eli
7 Rock-Solid Healthcare Dividend Stocks to Buy in January
09:10am, Saturday, 06'th Jan 2024
The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi
Novartis (NVS) Beats Stock Market Upswing: What Investors Need to Know
07:33pm, Friday, 05'th Jan 2024
In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.
NVS or LLY: Which Is the Better Value Stock Right Now?
12:47pm, Friday, 05'th Jan 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity
MDMA therapy company Lykos raises $100M in Series A funding as it eyes FDA approval
08:00am, Friday, 05'th Jan 2024
MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first
Voyager Therapeutics' Novartis deal has analysts bullish on stock's long-term outlook
02:56pm, Tuesday, 02'nd Jan 2024
Voyager Therapeutics' announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapies
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments
02:20pm, Tuesday, 02'nd Jan 2024
Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illness
Voyager Therapeutics shares pop on collaboration with Novartis worth up to $1.2B
07:58am, Tuesday, 02'nd Jan 2024
Voyager Therapeutics Inc (NASDAQ:VYGR) shares rallied more than 30% in Tuesday pre-market trading after the company announced a strategic collaboration and capsid license agreement worth up to $1.2 bi
Your New Year's Resolution For 2024: Invest $10,000 In These 5 Stocks
02:54pm, Friday, 29'th Dec 2023
I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.
These 3 Big Pharma Stocks Are Making Big Plays With AI
07:15am, Friday, 22'nd Dec 2023
Big drug companies want to use artificial intelligence for a handful of purposes. Finding leads to make medicines more efficiently is one in-demand application.
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
07:32pm, Thursday, 14'th Dec 2023
In the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day.
6 Health Care Dividend Stocks To By Hand Over Fist
10:48am, Monday, 11'th Dec 2023
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
01:48pm, Sunday, 10'th Dec 2023
Chimeric antigen receptor T-cell medicines could have more risks than previously known. Novartis' drug Kymriah is going to be under the most scrutiny for now.
10 Buffett-Style Dividend Aristocrats Yielding As Much As 10%
07:35am, Saturday, 02'nd Dec 2023
Stocks are having their best November in 43 years, and stocks are now 13% historically overvalued. But thankfully, smart investors can always find incredible Warren Buffett-style bargains, both of the
